𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Lack of beneficial effects of clonidine in the treatment of premenstrual dysphoric disorder: results of a double-blind, randomized study

✍ Scribed by Robertas Bunevicius; Alan L. Hinderliter; Kathleen C. Light; Cort A. Pedersen; Susan S. Girdler

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
81 KB
Volume
20
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Objectives To test the effects of clonidine in comparison with active placebo on premenstrual symptoms, mood scores and norepinephrine (NE) concentration, in women with premenstrual dysphoric disorder (PMDD). Methods Twelve women with prospectively confirmed PMDD were randomly assigned to oral 0.3 mg/day clonidine, as an active treatment, or 10 mg/day loratadine, as an active placebo, for 2 months each using a double-blind, cross-over design. NE concentration, premenstrual symptom ratings and mood scales were measured on three occasions: at pretreatment, after clonidine treatment and after placebo treatment. All patients were free of current psychiatric co-morbidity and medication use. Results There were no significant differences between clonidine and placebo for mood scales or premenstrual symptom ratings, though clonidine significantly suppressed NE concentration and produced more side effects in comparison with placebo. Conclusion Compared with an active placebo clonidine demonstrated no beneficial changes in mood and premenstrual symptoms in women with PMDD.

πŸ“œ SIMILAR VOLUMES

Alefacept in combination with methotrexa
Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: Results of a randomized, double-blind, placebo-controlled study
✍ Philip J. Mease; Dafna D. Gladman; Edward C. Keystone πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 165 KB πŸ‘ 2 views

## Abstract ## Objective To evaluate the efficacy and safety of alefacept in combination with methotrexate (MTX) for the treatment of psoriatic arthritis (PsA). ## Methods Patients were eligible for this randomized, double‐blind, placebo‐controlled trial if they were ages 18–70 years and had act

Celecoxib as an adjunct in the treatment
Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study
✍ Fabiano G. Nery; Emel S. Monkul; John P. Hatch; Manoela Fonseca; Giovana B. Zunt πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 117 KB

## Abstract ## Objective To investigate whether the cox‐2 inhibitor celecoxib has antidepressant effects in bipolar disorder (BD) patients during depressive or mixed phases. ## Methods We studied 28 DSM‐IV BD patients who were experiencing a depressive or mixed episode and were on a stable dose

Sulfasalazine in the treatment of juveni
Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter study
✍ Marion A. J. van Rossum; Theo J. W. Fiselier; Marcel J. A. M. Franssen; Aeilko H πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 987 KB

Objective. To assess the efficacy, tolerability, and safety of sulfasalazine (SSZ) in the treatment ofjuvenile chronic arthritis (JCA). Methods. We conducted a 24-week randomized, placebo-controlled, double-blind, multicenter study of patients with active JCA of both oligoarticular and polyarticula